Carcinoma renal con carcinoma superior urotelial de aparición sincrónica y contralateral. Presentación de caso clínico
Clinical case presentation: A 71-year-old male patient presented with anemic syndrome and macroscopic hematuria. Utrotomography showed left renal cancer and urothelial tumor of the right upper urinary tract of synchronous appearance; Nephroureterectomy with bladder cuff on the right side and partial left nephrectomy were performed, both laparoscopically at the same surgical time. Relevance: Renal carcinoma represents 2-3 % of primary urological cancers, while upper tract urothelial carcinoma is a rare uroepithelial tumor whose incidence reaches 5-10 % of all urothelial carcinomas. While it is rare for urologic tumors to occur together, it is even rarer to find renal carcinoma combined with upper tract urothelial carcinoma; It is estimated that it occurs in 1.1 % of cases. Clinical implications: For the treatment of renal cancer combined with upper tract urothelial cancer, radical nephroureterectomy with contralateral partial nephrectomy remains the best treatment option showing good oncological results. Conclusions: The incidence of synchronous tumors increases simultaneously with the increase in the incidence of genitourinary tumors. Treatment represents a challenge for the urologist and must be individualized according to the patient's characteristics.
Authors
- Eddy Gabriel Muñoz-Lumbreras (ORCID: https://orcid.org/0000-0002-9036-980X)
- Jorge Antonio Valdéz-Colín (ORCID: https://orcid.org/0000-0002-7638-7278)
- José Juan Guadalupe Arias-Patiño (ORCID: https://orcid.org/0000-0001-7583-5158)
- Iván Aldair Peña Morales (ORCID: https://orcid.org/0000-0003-3988-159X)
- Oscar Daniel Guzmán Aguilar (ORCID: https://orcid.org/0000-0001-6348-6640)
Institutions
- Instituto de Salud del Estado de México (MX)
Publication Details
- Journal
- Revista Mexicana de Urología
- Published
- 2024-09-05
- DOI
- https://doi.org/10.48193/fvpfp034
- Primary Topic
- Renal cell carcinoma treatment
- Type
- article
- Field-Weighted Citation Impact
- 0.00